|
|
Article: Neurocrine Reports Phase III Indiplon Results In Patients With Chronic Insomnia; Indiplon Modified Release Shows Statistically Significant Improvement In Sleep Maintenance and Sleep Quality.
- Article from:
- PR Newswire
- Article date:
- September 24, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Neurocrine Biosciences, Inc. today announced preliminary top line results from the Company's first indiplon modified release Phase III clinical trial, achieving statistically significant results that demonstrate patients with chronic insomnia taking indiplon 30 mg fell asleep more rapidly and stayed asleep longer. The data released today support the objective results demonstrated with indiplon utilizing polysomnographic analyses of patients in previous clinical trials.
The modified release formulation of indiplon following nightly administration of 30 mg over a two week period demonstrated a statistically significant improvement in the primary endpoint of ...